Celsion (CLSN) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Celsion Corporation Reports Second Quarter 2016 Financial Results and Provides Business Update
August 15, 2016 9:02 AM EDTSignificant Progress in Immuno-oncology and Chemotherapy Clinical Research Complimented with a 20% Reduction in Operating Expenses
Company to Hold Conference Call on Monday, August 15, 2016 at 11:00 a.m. EDT
LAWRENCEVILLE, N.J., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter and six month period ended June 30, 2016 and provided an update on its development programs for ThermoDox®, the Companys proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA-based... More
Celsion Corporation Announces Final Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer
August 15, 2016 8:01 AM EDTSubgroup Data Continue to Show a Statistically Significant Improvement in Overall Survival, Consistent With a Two Year Median Survival Benefit Following Treatment with ThermoDox® plus Optimized RFA
Data from the Chinese Cohort of Patients Show Clinically Meaningful Benefit
LAWRENCEVILLE, N.J., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) today announced updated results from its final retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liver cancer,... More
